SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.139+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Interesting Times2/28/2025 6:30:40 PM
  Read Replies (1) of 1229
 
What's the situation with pancreatic cancer?

So in announcing Anktiva's FDA designation for reversal of Lymphopenia, IBRX also stated that it will file BLA "for the treatment of locally advanced or metastatic pancreatic cancer". Does anyone know if it is related to NCT05304936? It is a trial for using HCW9218 for Advanced Pancreatic Cancer. The study should be released any time now. The thing is, I don't think HCW9218 is directly Anktiva.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News